213 related articles for article (PubMed ID: 32984002)
1. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
Li H; Huang C; Zhang Z; Feng Y; Wang Z; Tang X; Zhong K; Hu Y; Guo G; Zhou L; Guo W; Xu J; Yang H; Tong A
Front Oncol; 2020; 10():1527. PubMed ID: 32984002
[TBL] [Abstract][Full Text] [Related]
2. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
3. A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity.
Feng Y; Xie K; Yin Y; Li B; Pi C; Xu X; Huang T; Zhang J; Wang B; Gu H; Fang J
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207448
[TBL] [Abstract][Full Text] [Related]
4. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
5. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma.
Zheng M; Yu L; Hu J; Zhang Z; Wang H; Lu D; Tang X; Huang J; Zhong K; Wang Z; Li Y; Guo G; Liu S; Tong A; Yang H
Transl Oncol; 2020 May; 13(5):100770. PubMed ID: 32298986
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
8. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
9. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
[TBL] [Abstract][Full Text] [Related]
10. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers.
Hu J; Jiang C; Zheng M; Guo Y; Tang X; Ren J; Lu D; Yu L; Gan W; Liu S; Tong A; Yang H
Am J Transl Res; 2019; 11(8):5183-5196. PubMed ID: 31497233
[TBL] [Abstract][Full Text] [Related]
12. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
[TBL] [Abstract][Full Text] [Related]
13. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
14. Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer.
Wang Y; Zhang Y; Sun H; Chen J; Yang H; Zhong Z; Xiao X; Li Y; Tang Y; Lu H; Tang X; Zhang M; Wu W; Zhou S; Yang J
Int Immunopharmacol; 2023 Oct; 123():110686. PubMed ID: 37499397
[TBL] [Abstract][Full Text] [Related]
15. Engineering MMP-2 Activated Nanoparticles Carrying B7-H3 Bispecific Antibodies for Ferroptosis-Enhanced Glioblastoma Immunotherapy.
Fan R; Chen C; Mu M; Chuan D; Liu H; Hou H; Huang J; Tong A; Guo G; Xu J
ACS Nano; 2023 May; 17(10):9126-9139. PubMed ID: 37097811
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
[TBL] [Abstract][Full Text] [Related]
17. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
[TBL] [Abstract][Full Text] [Related]
18. Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.
Mews EA; Beckmann P; Patchava M; Wang Y; Largaespada DA; Wagner CR
ACS Nano; 2022 Aug; 16(8):12185-12201. PubMed ID: 35876221
[TBL] [Abstract][Full Text] [Related]
19. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
20. B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8
You G; Lee Y; Kang YW; Park HW; Park K; Kim H; Kim YM; Kim S; Kim JH; Moon D; Chung H; Son W; Jung UJ; Park E; Lee S; Son YG; Eom J; Won J; Park Y; Jung J; Lee SW
Sci Adv; 2021 Jan; 7(3):. PubMed ID: 33523913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]